In 2025, Assembly Biosciences achieved a revenue of $72.3 million from collaborative research with Gilead, a substantial increase from $28.5 million in 2024. This growth reflects the successful licensing of the helicase-primase inhibitor (HPI) program, including candidates ABI-5366 and ABI-1179, to Gilead, which was prompted by positive Phase 1b interim data. The company received a net $35 million option fee under the ongoing collaboration agreement.
CEO Jason Okazaki expressed optimism about the company's trajectory, stating, "2025 was a pivotal year for the Company, and we anticipate another strong year ahead. Compelling Phase 1b data across ABI-5366 and ABI-1179 led to an early decision by Gilead to license the HPI program, validating the strength of our science and execution."
Looking ahead, Assembly Biosciences plans to initiate a Phase 2 clinical study for ABI-6250, an oral small-molecule entry inhibitor candidate for chronic hepatitis delta virus, by the end of 2026. The company is also set to determine whether to opt into a 40% U.S. cost-profit share for the herpesvirus HPI program by mid-2026, pending Gilead's development plan and budget.
The financial results reflect a net loss attributable to common stockholders of $6.1 million, or $0.55 per share, for the year ended December 31, 2025, a significant reduction from a net loss of $40.2 million, or $6.69 per share, in 2024. This improvement in net loss indicates better operational efficiency and financial management.
Overall, the positive developments in licensing agreements, increased revenue, and a strong cash position suggest that Assembly Biosciences is well-positioned for future growth and success in its clinical programs, particularly in the areas of herpes and hepatitis treatments.
